Filing Flows › CG Oncology (CGON) › Q4 2024
CG Oncology (CGON) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 28, 2025
CG Oncology (CGON) reported revenue of $456K for the fourth quarter 2024 (Q4 2024), up 456-fold from a year earlier and +960% from the quarter before.
CG Oncology, Q4 2024: revenue $456K (456× year over year), net loss $31.8M, operating cash flow −$20.7M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $456K | +960% | 456× |
| Operating profit | −$38.0M | — | — |
| Net earnings | −$31.8M | — | — |
| Operating cash flow | −$20.7M | — | — |
What changed
Revenue was $456K in Q4 2024, up 45500% year over year and up 960% from the previous quarter.
Operating costs exceeded revenue by $38.0M, an operating margin of -8344.1%. Total costs grew 99% against revenue growth of 45500%. The fastest-growing cost line was General & admin (+288%). The quarter ended with a net loss of $31.8M, wider than the previous quarter's $20.4M loss.
Operating cash flow was −$20.7M. Non-cash charges added back $5.0M of share-based compensation. Working capital and other items added $6.1M. Capital expenditures of $209K exceeded it, leaving free cash flow of −$20.9M.
Questions
What was CG Oncology's revenue in the fourth quarter 2024?
CG Oncology (CGON) reported revenue of $456K for the fourth quarter 2024 (Q4 2024), up 456-fold from a year earlier and +960% from the quarter before.
Source: CG Oncology 10-K on SEC EDGAR.